IMMP News and Press, Immutep Limited From 09/21/23

Media Release SYDNEY, AUSTRALIA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today ...

Verbund AG ADR (OEZVY) is expected to report for Q2 2023 Adtran Networks SE (ADVOF) is expected to report for Q2 2023 OMV AG (OMVJF) is expected to report $1.66 for Q2 2023 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 Minim Inc (MINM) is expected to r...

DocuSign Inc. (DOCU) is expected to report $0.11 for Q2 2024 Firm Capital Property Trust Unit (FRMUF) is expected to report for Q1 2024 LifeWorks Inc (MSIXF) is expected to report for quarter end 2023-06-30 Concrete Pumping Holdings Inc. (BBCP) is expected to report $0.16 for Q3 2023 ...

Immutep Limited (IMMP) is expected to report for Q4 2023

SYDNEY, AUSTRALIA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its manageme...

2023-09-01 18:57:51 ET Summary Immutep Limited is a small cap biotech focusing on the development of eftilagimod alpha, a novel molecule that activates MHC class II molecules to enhance the immune response. The company is conducting late-stage trials in head and neck cancer, non-s...

Media Release SYDNEY, AUSTRALIA, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today a...

Media Release Late-stage & registrational trial progress: TACTI-004 Phase III - Positive feedback received from US FDA for planned registrational trial in 1st line non-small cell lung cancer (1L NSCLC) TACTI-003 Phase IIb – Randomised study in 1st line head &...

Media Release Mini O ral presentation will include data from TACTI-002 Phase II trial evaluating chemotherapy-free IO combination of efti plus KEYTRUDA® ( pembrolizumab ) Two additional posters on investigator-initiated trials eva...

Media Release SYDNEY, AUSTRALIA, July 28, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today annou...